Lorna Swan is the Clinical Lead for Adult Congenital Heart Disease (ACHD) at the Royal Brompton Hospital, London  – one of the oldest and largest units in the world.  Lorna trained in Glasgow, London and Toronto. Her previous  roles have included being a council member of the British Congenital Cardiac Association and a nucleus member of the ESC GUCH Working Group. Her main interests include Pregnancy and Heart Disease and ACHD Heart Failure.Alexandra Frogoudaki runs the Adult Congenital Heart Disease Service at the University General Hospital ATTIKON in Athens. Prior to that she trained in Greece and London. She was the previous elected president of the Greek working group on ACHD and is currently the national coordinator of the ESC pregnancy register. Dr. Frogoudaki is the senior author of the ESC Heart Failure -ACHD position paper published in 2016.

Select Guide Rating

• 1 The growing population of ACHD patients.- 2 Incidence and prevalence of HF in ACHD.- 3 Causes of HF in ACHD.- 4 Assessment of the HF patient- Diagnosis.- 5 Risk stratification & prognosis.- 6 Non-medical treatment & lifestyle modification.- 7 Drug therapies.- 8 Device therapy & rhythm management.- 9 Mechanical support.- 10 Transplantation.- 11 Holistic care & palliation.- 12 Future research.- 13 Co-morbidities.- 14 Specific conditions - Fontan & univentricular heart.- 15 Specific conditions - Systemic RV.

Lorna Swan is the Clinical Lead for Adult Congenital Heart Disease (ACHD) at the Royal Brompton Hospital, London  – one of the oldest and largest units in the world.  Lorna trained in Glasgow, London and Toronto. Her previous  roles have included being a council member of the British Congenital Cardiac Association and a nucleus member of the ESC GUCH Working Group. Her main interests include Pregnancy and Heart Disease and ACHD Heart Failure.Alexandra Frogoudaki runs the Adult Congenital Heart Disease Service at the University General Hospital ATTIKON in Athens. Prior to that she trained in Greece and London. She was the previous elected president of the Greek working group on ACHD and is currently the national coordinator of the ESC pregnancy register. Dr. Frogoudaki is the senior author of the ESC Heart Failure -ACHD position paper published in 2016.

Select Guide Rating

• 1 The growing population of ACHD patients.- 2 Incidence and prevalence of HF in ACHD.- 3 Causes of HF in ACHD.- 4 Assessment of the HF patient- Diagnosis.- 5 Risk stratification & prognosis.- 6 Non-medical treatment & lifestyle modification.- 7 Drug therapies.- 8 Device therapy & rhythm management.- 9 Mechanical support.- 10 Transplantation.- 11 Holistic care & palliation.- 12 Future research.- 13 Co-morbidities.- 14 Specific conditions - Fontan & univentricular heart.- 15 Specific conditions - Systemic RV.

Lorna Swan is the Clinical Lead for Adult Congenital Heart Disease (ACHD) at the Royal Brompton Hospital, London  – one of the oldest and largest units in the world.  Lorna trained in Glasgow, London and Toronto. Her previous  roles have included being a council member of the British Congenital Cardiac Association and a nucleus member of the ESC GUCH Working Group. Her main interests include Pregnancy and Heart Disease and ACHD Heart Failure.Alexandra Frogoudaki runs the Adult Congenital Heart Disease Service at the University General Hospital ATTIKON in Athens. Prior to that she trained in Greece and London. She was the previous elected president of the Greek working group on ACHD and is currently the national coordinator of the ESC pregnancy register. Dr. Frogoudaki is the senior author of the ESC Heart Failure -ACHD position paper published in 2016.

Select Guide Rating

• 1 The growing population of ACHD patients.- 2 Incidence and prevalence of HF in ACHD.- 3 Causes of HF in ACHD.- 4 Assessment of the HF patient- Diagnosis.- 5 Risk stratification & prognosis.- 6 Non-medical treatment & lifestyle modification.- 7 Drug therapies.- 8 Device therapy & rhythm management.- 9 Mechanical support.- 10 Transplantation.- 11 Holistic care & palliation.- 12 Future research.- 13 Co-morbidities.- 14 Specific conditions - Fontan & univentricular heart.- 15 Specific conditions - Systemic RV.